Categories
Connect with us on LinkedIn
Where AI is actually saving time in eCOA, and the work it still can’t touch
The process for localizing patient questionnaires and moving them onto screens has barely changed in twenty years, while...
The UAT window is days. The eCOA study runs months. Here’s how AI bridges that gap.
eCOA systems contain time-dependent logic that unfolds over months of a live study: compliance windows, adaptive triggers, missed-visit...
AI in eCOA: What Works. What Breaks
AI is being applied to eCOA localization, but most teams are still figuring out where it genuinely helps...
Where PRO strategy goes wrong: therapeutic area fit, capture frequency, and the implementation gap that takes years to surface
Expert insights on PRO data, regulatory uncertainty, and the implementation gap that kills most ePRO strategies. Watch the...
The eCOA Iceberg: uncovering the hidden costs of software-only models
SaaS eCOA looks cheaper on paper. This guide exposes five hidden costs that change the full-service vs. software-only...
Leveraging the patient voice to reduce regulatory uncertainty during submission
Learn how PRO data closes evidence gaps in FDA and EMA submissions. Join outcomes expert Ari Gnanasakthy and...
The ePRO blueprint for pain trials: Optimizing data capture from protocol design to efficacy endpoints
The 11-point electronic Numeric Rating Scale (eNRS) is now the preferred digital standard for BYOD pain trials, recommended...
Castor adds nearly 10 commercial Phase II/III eCOA studies in H2 2025
Nearly 10 Phase II/III eCOA studies and 12 validated instruments across four therapeutic areas. Castor’s H2 2025 platform...
ICH E6(R3) compliance for biotech studies
See how Castor's unified platform helps biotech sponsors meet ICH E6(R3) oversight, data integrity, and site burden requirements.
ePRO for biotech: capture economic evidence from day one
Castor ePRO helps biotech sponsors capture HEOR-ready evidence from Phase I/II. Audit-proof, 92%+ participant compliance.
The real-time monitoring dilemma
Offline eCOA capability creates regulatory tension with EMA device-as-source requirements while eliminating real-time monitoring capabilities that drive 80-95%...
Is Your eCOA UAT Stuck in Time?
Modern clinical trials increasingly rely on complex, time-sensitive logic within eCOA systems, such as narrow compliance windows and...
The End of the “PRO Tax”: Top 10 Commercial PROs & their cost-effective alternatives
The clinical trial industry faces a "PRO Tax"—the high costs and operational delays associated with licensing and implementing...
The Silent Saboteurs: Why Rater Drift and Site Unpreparedness Cost CNS Trials More
CNS trials fail not from technology limitations but organizational factors. Research reveals 55% of sites lack adequate eCOA...
Hospital-Based eCOA Implementation: Real Challenges in Infectious Disease Trials
Hospital-based infectious disease trials face unique eCOA implementation challenges including IT security delays, staff turnover, and patient acuity...
Implications of Assessing Overall Survival in Oncology Studies
The FDA’s August 2025 draft guidance reshapes oncology clinical trials by requiring pre-specified overall survival (OS) analysis in...
The Patient Experience Paradox: eCOA Strategy Overhaul
Discover how the EMA’s new Patient Experience Data (PED) guidance and the EU HTA Regulation are reshaping evidence...
On-site ePRO in Action: A Recap of Castor’s Product Spotlight
Castor’s on-site ePRO adds in-clinic PRO capture to the ePRO/CDMS workflow you already use. Staff use a site...
Connect with us on LinkedIn
